ArticleNature cell biology2021
LIMIT is an immunogenic lncRNA in cancer immunity and immunotherapy.
Open access · greenAbstract read
In one paragraph
Article in Nature cell biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 119 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
119citing papers in PubMed, 2 pooled it
16.8field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
119 citing papers in PubMed, 2 syntheses or guidelines pooled it, 222 citations in OpenAlex.
- Long non-coding RNAs and their potential role in predicting immunotherapy response and prognosis: a systematic review.Frontiers in immunology · 2026Pooled it
- Prognostic values of long noncoding RNA in bone metastasis of prostate cancer: A systematic review and meta-analysis.Frontiers in oncology · 2023Pooled it
- Construction of PANoptosis-related lncRNA prognostic model and immunotherapy sensitivity analysis in lung adenocarcinoma.Journal of cardiothoracic surgery · 2026Article
- LISS enables immune evasion of colorectal cancers irrespective of MSI status.Signal transduction and targeted therapy · 2026Article
- GFI1 enhances MHC-I expression in tumor cells and augments tumor responsiveness to PD-1/PD-L1 inhibitors.Cancer immunology, immunotherapy : CII · 2026Article
- Article
- WFDC21P is essential for G3BP1-mediated RIG-I activation and antitumor immunity in triple-negative breast cancer.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- GBP2 condensates promote ferroptosis to sensitize anti-PD-L1 immunotherapy in melanoma.Nature communications · 2025Article
- RERE-AS1 as a regulator of immune modulation and therapeutic response in breast cancer.Cancer immunology, immunotherapy : CII · 2025Article
- Identification of GBP6 as a potential prognostic biomarker in esophageal carcinoma by integrated bioinformatics analysis and experiment validation.Annals of medicine · 2025Article
- A symphony of signals: the intricate role of lncRNAs in dermatological disorders.Clinical and experimental medicine · 2025Review
- Regulatory roles of LncRNAs in colorectal cancer immune evasion: current concepts and future perspectives.Discover oncology · 2025Review
- Targeting epigenetic regulators as a promising avenue to overcome cancer therapy resistance.Signal transduction and targeted therapy · 2025Review
- Characterization of Tumor Antigens from Multi-omics Data: Computational Approaches and Resources.Genomics, proteomics & bioinformatics · 2025Review
- Dynamic changes of synergy relationship between lncRNA and immune checkpoint in cancer progression.Briefings in bioinformatics · 2025Article
- Decoding MHC loss: Molecular mechanisms and implications for immune resistance in cancer.Clinical and translational medicine · 2025Review
- Functions and mechanisms of lncRNAs in immune escape and their application in immunotherapy for colorectal cancer.Journal of translational medicine · 2025Review
- Unraveling the advances of non-coding RNAs on the tumor microenvironment: innovative strategies for cancer therapies.Journal of translational medicine · 2025Review
- Dual roles of long non-coding RNAs in thyroid cancer: regulation of programmed cell death pathways.Medical oncology (Northwood, London, England) · 2025Review
- A Comprehensive Review of Long Non-Coding RNAs in the Cancer-Immunity Cycle: Mechanisms and Therapeutic Implications.International journal of molecular sciences · 2025Review
59 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
18 authors at 1 institution in 1 country.
Gaopeng LiDepartment of Surgery, University of Michigan, Ann Arbor, MI, USA.
Ilona KryczekDepartment of Surgery, University of Michigan, Ann Arbor, MI, USA.ORCID http://orcid.org/0000-0002-3130-2533
Jutaek NamDepartment of Pharmaceutical Sciences, University of Michigan, Ann Arbor, MI, USA.
Xiong LiDepartment of Surgery, University of Michigan, Ann Arbor, MI, USA.
Shasha LiDepartment of Surgery, University of Michigan, Ann Arbor, MI, USA.
Jing LiDepartment of Surgery, University of Michigan, Ann Arbor, MI, USA.
Shuang WeiDepartment of Surgery, University of Michigan, Ann Arbor, MI, USA.
Sara GroveDepartment of Surgery, University of Michigan, Ann Arbor, MI, USA.
Linda VatanDepartment of Surgery, University of Michigan, Ann Arbor, MI, USA.
Jiajia ZhouDepartment of Surgery, University of Michigan, Ann Arbor, MI, USA.
Wan DuDepartment of Surgery, University of Michigan, Ann Arbor, MI, USA.
Heng LinDepartment of Surgery, University of Michigan, Ann Arbor, MI, USA.
Ton WangDepartment of Surgery, University of Michigan, Ann Arbor, MI, USA.ORCID http://orcid.org/0000-0003-0437-3771
Chitra SubramanianDepartment of Surgery, University of Michigan, Ann Arbor, MI, USA.
James J MoonDepartment of Pharmaceutical Sciences, University of Michigan, Ann Arbor, MI, USA.
Marcin CieslikDepartment of Computational Medicine & Bioinformatics, University of Michigan, Ann Arbor, MI, USA.
Mark CohenDepartment of Surgery, University of Michigan, Ann Arbor, MI, USA.
Weiping ZouDepartment of Surgery, University of Michigan, Ann Arbor, MI, USA. wzou@med.umich.edu.ORCID http://orcid.org/0000-0001-7952-3549
University of Michigan · US
Funding
XenograftP30CA046592 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI THEODORE S LAWRENCE · 1988 to 2026
$178.2MTissue/InformaticsP50CA186786 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Robert Timothy Dess · 2014 to 2026
$27.6MUniversity of Michigan Surgical Oncology Research Training ProgramT32CA009672 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI JACQUELINE SARA JERUSS, WEIPING ZOU · 1991 to 2026
$6.0MNaive T cells in Cancer Immune Evasion and ImmunotherapyR01CA217510 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI ZOU, WEIPING · 2017 to 2021
$3.3MRegulatory T cells in cancer therapyR01CA244827 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI ZOU, WEIPING · 2021 to 2025
$3.2MMetabolic impact on T cell-mediated cancer immunity and therapyR01CA248430 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI ZOU, WEIPING · 2020 to 2024
$3.2MDevelopment and Evaluation of Purine and Coumarin Based Hsp90 Inhibitors`U01CA120458 · NCI · UNIVERSITY OF KANSAS LAWRENCE · PI BLAGG, BRIAN S J · 2007 to 2014
$2.6MMDSCs in Ovarian CancerR01CA193136 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI ZOU, WEIPING · 2015 to 2019
$2.5MDevelopment and Evaluation of Purine and Coumarin Based Hsp90 Inhibitors`R01CA120458 · NCI · UNIVERSITY OF NOTRE DAME · PI BLAGG, BRIAN S J · 2006 to 2019
$1.9MMemory T Cells in the Tumor MicroenvironmentR01CA152470 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI ZOU, WEIPING · 2011 to 2015
$1.9MHuman Tregs in Ovarian CancerR01CA099985 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI ZOU, WEIPING · 2006 to 2014
$1.8MNovel immunosupressive macrophages in human ovarian tumorR01CA123088 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI ZOU, WEIPING · 2007 to 2011
$1.4MNCI NIH HHS P30 CA046592NCI NIH HHS P50 CA186786NCI NIH HHS R01 CA099985NCI NIH HHS R01 CA120458NCI NIH HHS R01 CA123088NCI NIH HHS R01 CA152470NCI NIH HHS R01 CA193136NCI NIH HHS R01 CA213566NCI NIH HHS R01 CA216919NCI NIH HHS R01 CA217510NCI NIH HHS R01 CA244827NCI NIH HHS R01 CA248430NCI NIH HHS T32 CA009672NCI NIH HHS U01 CA120458
Abstract
Major histocompatibility complex-I (MHC-I) presents tumour antigens to CD8
Indexed as
ImmunotherapyAntigens, NeoplasmCD8-Positive T-LymphocytesCell Line, TumorHSP90 Heat-Shock ProteinsHumansNeoplasmsRNA, Long NoncodingSignal TransductionAntigens, NeoplasmHSP90 Heat-Shock ProteinsRNA, Long Noncoding
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.